Drugs / 68Ga-Galmydar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07838649 | Nov 2026 → Dec 2029 expected | Hodgkins lymphoma, breast cancer, non-Hodgkin lymphoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-Galmydar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07838649 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-Galmydar is a positron-emitting radioisotope used prior to PET/MRI imaging.” NCT07838649 ↗ |
| Route | Intravenous | “one single intravenous administration” NCT07838649 ↗ |